Background: Screening of malignant hematological diseases is of great importance for their diagnosis and subsequent treatment. This study constructed an optimal screening model for malignant hematological diseases based on routine blood cell parameters.

Methods: The venous blood samples of 1751 patients collected from 10 tertiary hospitals in China were divided into a training set (1223 cases) and a validation set (528 cases). In addition to the clinical diagnostic information of the samples in the training set, 26 blood cell parameters including morphological parameters were selected using manual screening and filtering to construct eight machine learning models. These models were used to identify hematological malignancies among the validation set.

Results: Comparison of the discrimination, calibration and clinical detection performance of the eight machine learning models revealed that the artificial neural network (ANN) model performed the optimal in identifying malignant haematological diseases in the validation set (528 cases), with an area under the receiver operating characteristic curve (AUC), accuracy, sensitivity and specificity of 0.906, 0.857, 0.832 and 0.884, respectively.

Conclusion: The ANN model constructed can be used for screening of malignant hematological diseases, especially in primary hospitals that lack comprehensive diagnosis, and this ANN model will help patients to get diagnosis and treatment of malignant hematological diseases as early as possible.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11816569PMC
http://dx.doi.org/10.1186/s12911-025-02892-1DOI Listing

Publication Analysis

Top Keywords

malignant hematological
20
hematological diseases
20
screening malignant
12
machine learning
12
blood cell
12
ann model
12
cell parameters
8
training set
8
validation set
8
set 528
8

Similar Publications

QuANTUM-First (NCT02668653) was a randomized phase 3 trial in newly diagnosed FLT3-ITDQpositive acute myeloid leukemia (AML) patients treated with quizartinib or placebo plus standard induction and consolidation chemotherapy and/or allogeneic hematopoietic cell transplantation (allo-HCT), followed by single-agent maintenance therapy. We evaluated the impact of allo-HCT performed in first complete remission (CR1) or composite CR1 (CRc1) on overall survival (OS), considering treatment randomization. Post-hoc extended Cox regression multivariable analyses were conducted in patients who achieved CR/CRc by the end of induction, including allo-HCT in CR1/CRc1 as a time-dependent variable to identify prognostic and predictive factors for OS.

View Article and Find Full Text PDF

Bruton tyrosine kinase covalent inhibition shapes the immune microenvironment in chronic lymphocytic leukemia.

Haematologica

March 2025

Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain; Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra.

Continuous treatment with ibrutinib not only exerts tumor control but also enhances T cell function in patients with chronic lymphocytic leukemia (CLL). We conducted longitudinal multi-omics analyses in samples from CLL patients receiving ibrutinib upfront to identify potential adaptive mechanisms to Bruton tyrosine kinase (BTK) inhibition during the first 12 months of continuous therapy. We found that ibrutinib induced a decrease in the expression of exhaustion markers and the proportion of Tregs and Tfh cells normalized to levels observed in healthy donors.

View Article and Find Full Text PDF

Case Report: Coexistence of Rosai-Dorfman disease and B-cell acute lymphoblastic leukemia in an adolescent.

Front Pediatr

February 2025

Pediatric Congenital Hematologic Disorders Research Center, Research Institute for Children's Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Rosai-Dorfman disease (RDD) is an unusual, non-malignant proliferative disorder involving non-Langerhans cell histiocytes, characterized by a wide range of clinical presentations and distinctive atypical morphological patterns. The concurrent manifestation of acute lymphoblastic leukemia (ALL) alongside RDD is exceptionally rare. Here, we present the case of a 14-year-old male patient diagnosed with ALL who, during the consolidation phase of chemotherapy, developed multifocal bone, dural, and liver lesions, as confirmed through CT and MRI imaging.

View Article and Find Full Text PDF

Introduction: Older patients with acute myeloid leukemia (AML) respond poorly to standard induction therapy. DNA methyltransferases (DNMTs) and histone-deacetylases (HDACs) are key regulators of gene expression in cells and have been investigated as important therapeutic targets. However, their effects remains unclear as induction therapy for AML.

View Article and Find Full Text PDF

Introduction: CD20+ T-cells were described firstly in peripheral blood and later in bone marrow in patients with hematological tumors, and certain immune-mediated diseases. During our hematological diagnostic work, this peculiar subgroup of lymphocytes has been consistently observed associated with untreated monoclonal gammopathy of undetermined significance (MGUS) and myeloma (MM). Despite the expanding literature data, the exact function of CD20+ T cells remains unclear.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!